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Objectives: The purpose of this study was to assess the magnitude of hypoglycemia 
barrier in terms of physician’s treatment choices and algorithm and the impact of 
hypoglycemia in adherence and persistence to insulin treatment. MethOds: Four 
hundred thirteen Turkish physicians were interviewed by close ended questions 
with a mix of dichotomous or bounded continuous response formats. Questions 
were asked face to face in 2 national diabetes congresses, with a physician mix of 
75% internists, 23% endocrinologists, 1,9% family physicians and rest pediatricians 
and obstetrics. Results: Within 413 replies on how important is the hypoglyce-
mia barrier to reach the target HbA1c on an importance scale, 95% replied either 
important or very important. 82% of physicians declared that they would change 
their target HbA1c, if they were not concerned about hypoglycemia. Similarly, 88% 
of physicians believed more of insulin-treated patients might reach target HbA1c 
if physicians are not concerned about hypoglycemia. Among the physicians replied 
79% stated that less than 40% of their patients reported their hypoglycemic status. 
If patients experience hypoglycemia, 75% of physicians would reduce the insulin 
dose for more than 60% of patients, 85% would stop insulin treatment for less than 
20% of patients, 91% would switch to other insulins and 62% would to prefer to keep 
same treatment for less than 20% of the patients. Among the physicians replied, 
35% of them declared that patients are willing to stop treatment due to hypoglyce-
mia and more than 50% declared that patient needs a new insulin that causes less 
hypoglycemia. cOnclusiOns: In this study, physician dimension of hypoglycemia 
was explored. From the results obtained, it is obvious for the Turkish physicians 
that hypoglycemia is perceived as a major barrier for the better treatment of the 
patients. These results show that new treatment options causing less hypoglycemia 
are needed in the treatment of diabetes mellitus.
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Objectives: The rational treatment of all diseases, but especially a chronic disease 
that have common systemic effects, medium and long-term complications such as 
diabetes is extremely important. The aim of the study is to understand medicine 
utilization in type II diabetes in Turkey. MethOds: In order to examine this topic, 
the volume and costs of anti-diabetics, preference rates of the active substances, 
first prescription behavior of physicians were taken from data base (MEDULA) of 
Social Security Institution, the government based reimbursement agency of Turkey 
from year 2007-2014. Descriptive analysis was conducted. Results: Consumption 
of diabetic medicines rose from 638 million TL to 1.116 million TL between 2007 and 
2013, respectively. The majority of the increase came from insulin and analogs that 
rose from 254 million TL to 664 million TL between 2007 to and 2013, respectively. 
84,17% of naïve diabetic patients had been started with anti(?) diabetic protocols 
without insulin in 2013. In additional, metformin was used as 76,24% of all patients 
in 2013 among them. 65,4% of diabetic patients diagnosed between 40-64 age in 2013. 
Approximately 70% of all patients were diagnosed by internal physicians in 2013, 
that ratio seems grooving in recent years. cOnclusiOns: Diabetic medicines are 
one of the mostly consuming medicines in Turkey. In additional, the consumption of 
diabetic medicines was is rising each every year. Diabetic protocols without insulin 
or including metformin have the highest percentage of all treatment protocols. 
Patients were diagnosed with internal physicians while it was expected as family 
physicians depending on clinical guidelines. The analysis may be a guide for poli-
cymakers to understand how the diabetes is managing in Turkey.
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Objectives: Insulin degludec (IDeg) is a long acting basal insulin analogue used 
once-daily in patients with Type 1 and Type 2 diabetes and was approved for use 
in Europe in 2013. A survey among clinicians was conducted to understand the 
initial real world experience from prescribing IDeg. MethOds: Clinicians with 
experience of prescribing IDeg in Germany, Sweden, Luxembourg, Switzerland 
and United Kingdom were invited to answer a short questionnaire in four waves. 
Collected data reflected the type of patients using IDeg, and the realised benefits 
of treatment including reductions in insulin dosing. Patients were not identifi-
able, and responses were anonymised, and qualitative or quantitative analyses 
used where appropriate. Results: In total, 226 clinicians (n) representing 3,083 
patients (pts) responded. In Germany (n= 201), clinicians reported a slight prefer-
ence to use IDeg for patients with T2DM versus patients with T1DM (34.5% versus 
25.5% respectively, with 35.5% stating T1DM and T2DM). Overall, reported clinical 
benefits included improvement in blood glucose control (n= 93, pts= 1440), flex-
ibility for patients (n= 69; pts= 1072) and reduced risk of hypoglycaemia (n= 55, 
pts= 939). Switching to IDeg allowed dose reductions in most patients (44% (n= 100) 
of clinicians representing 55% (n= 1690) of patients). Overall, 74% of clinicians 
(n= 168; pts= 1,856) reported the flexible dosing schedule had a positive impact on 
patients. cOnclusiOns: These early findings in Germany and other European 
countries confirm the results from IDeg randomised clinical trials and indicate real 
world experience with IDeg is positive for both clinicians and patients by adding 
valuable treatment benefits.
PDB139
cUrrent clinicAl PrActice corresPonDence With treAtMent 
gUiDelines in PAtients With tyPe 2 DiABetes MellitUs
Chandran A1, Parisi M1, Saltiel-Berzin R1, Bonafede MM2
1Becton Dickinson, Franklin Lakes, NJ, USA, 2Truven Health Analytics, Cambridge, MA, USA
in Malaysia. Undiagnosed and failure to achieve trio Hs treatment goals further 
increased complication and severity of the chronic conditions. Hyperlipidemia 
was highly underdiagnosed and efforts are needed to manage these conditions 
in holistic manner rather than isolation.
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Objectives: For patients with T2DM does telemedicine, compared with standard 
care, provide equivalent clinical outcomes? MethOds: Forty patients with type 2 
diabetes mellitus allocated from October 2011 until July 2012 randomized to either 
treatment at home by video conferences only or the standard outpatient treatment. 
Primary outcomes were HbA1c and blood glucose levels and secondary outcomes 
were 24-h blood pressure, cholesterol levels, and albuminuria. The videotelephone 
was installed and serviced by the telephone company, TDC, Denmark, as a broadband 
solution. Results: The improvements in the two treatments, given as changes in 
percent of telemedicine vs. standard, showed significant differences in HbA1c (-15 
vs. -11 %), mean blood glucose (-18 vs. -13 %,.and in cholesterol (-7 vs. -6 %). No dif-
ferences in LDL (-4 vs. -6 %), weight (-1 vs. 2 %), diastolic diurnal blood pressure (-1 
vs. -7 %), and systolic diurnal blood pressure (0 vs. -1 %) were found. Nine consulta-
tions were missed in the standard outpatient group and none in the telemedicine 
group. cOnclusiOns: The direct comparison of home video consultations versus 
standard outpatient treatment in T2DM, telemedicine was a safe and superior option 
in treatment of T2DM with equivalent or better outcome after six months treatment.
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Objectives: Diabetic foot ulcer (DFU) is the most serious and disabling long term 
complication of diabetes, adversely affecting the health related quality of life 
(HRQoL). This study evaluates the impact of patient-education on HRQoL of DFU 
patients. MethOds: This open-labeled randomized controlled study on the effect 
of patient-education on improvement of HRQoL, conducted in Kasturba Medical 
College Hospital, Manipal, (coastal South India), consisted of 120 DFU patients with 
60 subjects each in the control group [CG] and intervention group [IG]. RAND-36 
questionnaire was employed for evaluating HRQoL scores of DFU patients in both 
groups at baseline and after six months of educational intervention. Results: 
Subjects in the both IG and CG reported poor HRQoL scores, (similar in each group) 
on all the eight subscales at baseline. But, after six months of educational interven-
tion, HRQoL improved substantially in IG with respect to CG as well as IG at baseline 
(p< 0.05). Likewise, in both CG and IG, the physical component summary scale (PCS) 
scores (22.9±6.4 vs 24.4± 7.6) and the mental component summary scale (MCS) 
scores (26.1±5.2 vs 27.6±7.3) were similar and poor before educational intervention. 
However, six months post educational intervention, in IG, the Both PCS and MCS 
scores increased dramatically from 24.4± 7.6 to 41.8±8.6 and 27.6±7.3 to 47.6±5.6 
(p< 0.05) respectively. cOnclusiOns: The remarkable improvement in the HRQoL 
in IG at six months follow-up suggests that patient-education significantly improves 
HRQoL in DFU patients. Overworked physicians and paucity of trained doctors in 
resource-poor settings obligate task-shifting to non-physician healthcare providers. 
Educational intervention is an economical and feasible strategy, especially in the 
context of the ever-increasing burden of non-communicable disease in resource-
poor developing world.
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Objectives: To give knowledge about diabetes and health, to prevent from diabetes 
employees at Health clinic at Songino khairkhan district. MethOds: Survey card 
with 12 questions has been given to 50 professionals, staff and employees which 
was randomly chosen, agreed to fill out survey and who has never been diagnosed 
with diabetes and working in a shift of health clinic. Blood glucose determination 
and body mass index tools are defined by medical instruments and apparatus. 
Survey was carried out from April, 2014 to July, 2014. Research data and results were 
developed by using the software “SPSS -11.5”. Results: 9 employees (38%) were 
30-39 years of age with an average age of 38.6 ± 9, and 44 of them were (88%) female 
and 24 of them were (48%), non-medical professionals, and 32 of them have never 
been done blood sugar test (64%). DISCUSSION: Our research result was related 
with people’s living condition who uses high calorie food because diabetes research 
of Fukashima, M. &Ogowa, K. (2008) have determined that people in the big cities 
uses high calorie foods, and rich carbohydrates food and have physical inactivity 
comparing with people who are living in the countryside. CONCLUSION: The aver-
age age of respondents were 38.6 ± 9, and 15 of them were 40-49 years old.(30%) 32 
of the employees have never given glucose test before (64%) and 15 of them had 
(30%) glucose monitored with 7.6. And 20 of them had heavy weight (40%), and 26 
of them worked for 24 hours (52%).
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